SCHEMBL1737581

SCHEMBL1737581

c1ccc2ncc(-n3ccc(CCCN4CCOCC4)n3)cc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 9/20 0.49
AKR1C3 P42330 1/20 0.45
PDE10A Q9Y233 1/20 0.45
POLB P06746 3/20 0.42
HTR3A P46098 1/20 0.42
DRD3 P35462 2/20 0.41
DRD2 P14416 1/20 0.41
LMNA P02545 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 2/20 0.40
NPC1 O15118 2/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
RAD52 P43351 1/20 0.40
RAB9A P51151 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1740599 0.81 SIGMAR1 (0.60) SIGMAR1AKR1C3POLBHTR3ADRD3
SCHEMBL1738602 0.78 SIGMAR1 (0.61) SIGMAR1AKR1C3HTR3ADRD3DRD2
SCHEMBL1738810 0.71 SIGMAR1 (0.72) SIGMAR1
SCHEMBL1739361 0.71 SIGMAR1 (0.75) SIGMAR1HTR2B
SCHEMBL2280216 0.71 AKR1C3 (0.73) AKR1C3POLBHTR3ALMNAKDM4E
SCHEMBL1738593 0.69 SIGMAR1 (0.46) SIGMAR1POLBDRD3DRD2LMNA
SCHEMBL3142440 0.68 SIGMAR1 (0.48) SIGMAR1CYP11B2
SCHEMBL1740562 0.67 SIGMAR1 (0.76) SIGMAR1HTR2B
SCHEMBL19597688 0.67 POLB (0.59) SIGMAR1POLBLMNAKMT2AKDM4E
SCHEMBL12123855 0.66 ALDH1A1 (0.61) AKR1C3LMNAKMT2AKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2576543-B1 PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS ESTEVE LABOR DR (ES) 2016-12-21 EP claimed
US-9181195-B2 Sigma receptor inhibitors LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2015-11-10 US claimed
US-20130158029-A1 SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2013-06-20 US claimed
EP-2576543-A1 PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS Laboratorios del Dr. Esteve S.A. (ES) 2013-04-10 EP claimed
EP-2395003-A1 Pyrazole compounds as sigma receptor inhibitors Laboratorios Del. Dr. Esteve, S.A. (ES) 2011-12-14 EP claimed
WO-2011147910-A1 PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2011-12-01 WO claimed
EP-3233078-A1 USE OF SIGMA RECEPTOR LIGANDS IN OSTEOARTHRITIS Laboratorios Del. Dr. Esteve, S.A. (ES) 2017-10-25 EP disclosed
US-20170273948-A1 USE OF SIGMA RECEPTOR LIGANDS IN OSTEOARTHRITIS LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2017-09-28 US disclosed
EP-2576543-B1 PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS ESTEVE LABOR DR (ES) 2016-12-21 EP disclosed
EP-2576543-B1 PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS ESTEVE LABOR DR (ES) 2016-12-21 EP disclosed
WO-2016096125-A1 USE OF SIGMA RECEPTOR LIGANDS IN OSTEOARTHRITIS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2016-06-23 WO disclosed
US-9181195-B2 Sigma receptor inhibitors LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2015-11-10 US disclosed
US-9181195-B2 Sigma receptor inhibitors LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2015-11-10 US disclosed
US-9181195-B2 Sigma receptor inhibitors LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2015-11-10 US disclosed
US-20130158029-A1 SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2013-06-20 US disclosed
US-20130158029-A1 SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2013-06-20 US disclosed
US-20130158029-A1 SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2013-06-20 US disclosed
EP-2395003-A1 Pyrazole compounds as sigma receptor inhibitors Laboratorios Del. Dr. Esteve, S.A. (ES) 2011-12-14 EP disclosed
WO-2011147910-A1 PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2011-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158029-A1 SIGMA RECEPTOR INHIBITORS SIGMAR1, TMEM97, OPRL1 SIGMAR1 1/4885AKR1C3 786/4885PDE10A 1309/4885
US-20170273948-A1 USE OF SIGMA RECEPTOR LIGANDS IN OSTEOARTHRITIS SIGMAR1, OPRL1, OPRK1 SIGMAR1 1/4885AKR1C3 831/4885PDE10A 1433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.